bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
The purpose of operando spectroscopy is to measure the catalytic changes that occur within the reactor during operation using time-resolved (and sometimes spatially-resolved) spectroscopy. Time-resolved spectroscopy theoretically monitor the formation and disappearance of intermediate species at the active site of the catalyst as bond are made and broken in real time. However, current operando instrumentation often only works in the second or subsecond time scale and therefore, only relative concentrations of intermediates can be assessed. Spatially resolved spectroscopy combines spectroscopy with microscopy to determine active sites of the catalyst studied and spectator species present in the reaction.
This is mathematically incorrect (if the rule was precisely accurate the required temperature increase would be about 15.8 °C (28.4 °F)), and in any case the rule is only a rough approximation and cannot always be relied on. Chemists often use the more comprehensive Arrhenius equation for better estimations. The same is true, up to a point, of the chemical reactions of living things. They are usually catalyzed by enzymes which change reaction rates, but with no variation in catalytic action, the rule of thumb is still mostly applicable. In the case of bacteria and fungi, the reactions needed to feed and reproduce speed up at higher temperatures, up to the point that the proteins and other compounds in their cells themselves begin to break down, or denature, so quickly that they cannot be replaced. This is why high temperatures kill bacteria and other micro-organisms: 'tissue' breakdown reactions reach such rates that they cannot be compensated for and the cell dies. On the other hand, 'elevated' temperatures short of these result in increased growth and reproduction; if the organism is harmful, perhaps to dangerous levels. Just as temperature increases speed up reactions, temperature decreases reduce them. Therefore, to make explosives stable for longer periods, or to keep rubber bands springy, or to force bacteria to slow down their growth, they can be cooled. That is why shelf life is generally extended by temperature control: (refrigeration, insulated shipping containers, controlled cold chain, etc.) and why some medicines and foods must be refrigerated.
"The Nixon White House panicked," wrote political editor Christopher Caldwell, and declared drug abuse "public enemy number one". By 1973, there were 1.5 overdose deaths per 100,000 people. There were fewer than 3,000 overdose deaths in 1979, when a heroin epidemic was raging in U.S. cities. There were fewer than 5,000 recorded in 1988, around the height of the crack epidemic. More than 64,000 Americans died from drug overdoses in 2016, according to the U.S. Centers for Disease Control and Prevention. Modern prescription opiates such as Vicodin and Percocet entered the market in the 1970s, but acceptance took several years and doctors were apprehensive about prescribing them. Until the 1980s, physicians had been taught to avoid prescribing opioids because of their addictive nature. A brief letter published in the New England Journal of Medicine (NEJM) in January 1980, titled "Addiction Rare in Patients Treated with Narcotics", was frequently cited to downplay such concerns. The NEJM reexamined the 1980 letter in June 2017, pointing out among other things that the conclusions were based on hospitalized patients only, and not on patients taking the drugs after they were sent home. The letter's original author, Hershel Jick, has said that he never intended for it to justify widespread opioid use.
Sources: en.wikipedia.org
In 2018, McGregor starred as the adult version of the titular character in Christopher Robin, a live-action adaptation of Disney's Winnie the Pooh franchise directed by Marc Forster and starred alongside Hayley Atwell. In 2019, McGregor starred as the older Danny Torrance in Doctor Sleep, the film adaptation of Stephen King's novel of the same name. In 2020, he appeared opposite Margot Robbie in Warner Bros.' DC Comics film Birds of Prey (and the Fantabulous Emancipation of One Harley Quinn), directed by Cathy Yan, as the main villain Roman Sionis / Black Mask. On 23 August 2019, Lucasfilm announced that McGregor would reprise his role as Obi-Wan Kenobi in a new Star Wars television series, which was released on Disney+ in 2022. In 2021, McGregor played the American fashion designer Halston in the eponymously titled miniseries for Netflix, based on the candid biography Simply Halston by journalist Steven Gaines. McGregor was also billed as executive producer, jointly with Ryan Murphy. In 2022, McGregor voiced Sebastián J. Cricket, the conscience and narrator, in Pinocchio. The film was directed by Guillermo del Toro and premiered on Netflix. In September 2024, McGregor received his star on the Hollywood Walk of Fame. In 2026, he had a starring role as Greg Platt in the science fiction survival film The End of Oak Street.
=== Anti-hypoxant === Bemethyl has been shown to preserve both physical and mental capacity in high-altitude, low-oxygen environments, particularly by its effect in helping control excess serum levels of cholesterol and bilirubin, which are known to have negative effects especially during adjustment to high-altitude environments.
White sharks are estimated to reach over 70 years of age. A 2018 study of sharks off eastern Australia and New Zealand found that juveniles had an annual survival rate of over 70%, while adults exceeded 90%. White sharks are sometimes preyed on by orcas, with which they also likely compete for food. The first recorded orca predation occurred at the Farallon Islands in 1997 when an estimated 4.7–5.3 m (15–17 ft) female orca killed an estimated 3–4 m (10–13 ft) white shark. Another similar attack apparently occurred there in 2000, but its outcome is not clear. Orca predation has since been documented on white sharks in other areas. Around South Africa, orcas typically hunt white sharks in groups of two to six. By flipping the sharks belly up, the whales trigger a paralytic state known as tonic immobility, allowing them to precisely target and consume the sharks' energy-rich livers. In 2017, a live white shark was sighted with purported orca teeth marks, providing the first evidence of the species surviving such an attack. White sharks often evacuate an area when orcas arrive, as has been documented both off South Africa and California. However, a 2026 study near Neptune Islands concluded that orcas alone are unlikely to cause white sharks to leave an area long-term. In addition to orcas, white sharks may fall prey to other sharks, including older white sharks, as pups and juveniles.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.